Challenges and future directions in adjuvant PDAC vaccines Building on the promising early-phase vaccine studies in MRD, several phase II trials aim to further validate these approaches. The AMPLIFY-7P trial (NCT05726864) is investigating the next-generation amphiphile vaccine targeting multiple KRAS mutations, building on findings from the phase I AMPLIFY-201 study, and focusing on robust T cell responses as a correlate for relapse-free survival.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Sarah E.
Contact Sarah E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack